Robotic Gait denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for robotic gait are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Robotic Gait Training as Experimental

Blue Cross Blue Shield frequently denies robotic-assisted gait training under an "experimental or investigational" classification, arguing that the evidence base does not yet meet the plan's threshold for established clinical benefit. This denial is common even though robotic gait training systems have been in clinical use for many years at major rehabilitation centers and appear in the guidelines of recognized rehabilitation medicine organizations. BCBS's experimental determination is based on its own technology assessment criteria — typically requiring a specific level of published evidence — and may not reflect current rehabilitation medicine consensus.

Experimental denials are among the most challenging but also the most consequential appeals, because if the determination is overturned, it typically unlocks coverage prospectively. Independent external reviewers in this space often have rehabilitation medicine expertise that exceeds the BCBS internal reviewer's, making external review particularly valuable.

## Your Appeal Rights

Under ACA Section 2719, experimental/investigational denials are adverse benefit determinations subject to internal appeal and independent external review — external review is particularly important here because the reviewer must be an independent clinical expert, not a BCBS employee. Under ERISA Section 503, employer-sponsored plans must provide full-and-fair review. File an internal appeal within 180 days of denial. Request external review within four months of the final internal denial. Expedited review is available for urgent clinical needs.

## Building a Strong Experimental-Denial Appeal

The goal is to show that robotic gait training meets BCBS's own criteria for established therapy — or, in the alternative, that BCBS's criteria are unreasonable as applied to this patient.

Documentation to assemble: - Prescribing physiatrist or neurologist letter that addresses the experimental classification directly, references the relevant rehabilitation medicine society guidelines by organization name, and explains the clinical evidence base in general terms without citing specific trial statistics - Diagnosis and functional assessment: the underlying condition, current severity, prior rehabilitation history, and why the patient is an appropriate candidate - Documentation from the treating rehabilitation center of their clinical protocol and experience with this modality - BCBS's published technology assessment or medical policy for robotic gait training — request it in writing, then map each criterion for "established" therapy to the published evidence base (by organization, not by statistic)

## Criteria-Mapping Structure

Obtain BCBS's experimental/investigational policy and their medical policy for robotic-assisted gait training. Most experimental policies list criteria a technology must meet to be considered non-experimental (e.g., recognition by professional societies, peer-reviewed publication, regulatory clearance).

For each criterion: - Experimental policy criterion: [copy verbatim] - Evidence that criterion is met: [describe, by reference to recognized organizations and regulatory status — no trial names, no statistics]

Note that FDA clearance of the specific robotic device (if applicable) is relevant — FDA 510(k) clearance or De Novo authorization is strong evidence that a device is not investigational.